Bal Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+2.8%−10.7%+11.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.9%−6.2%+25.5%
+5.2%−7.8%+34.2%
−12.2%−3.3%+184.3%
−13.4%−7.7%+195.8%
+11.9%+4.8%+2.3%
+6.3%+11.8%+8.7%
+48.7%−93.7%+1,330.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALPHARMA₹84.61

Bal Pharma Limited

· Pharma & Health
₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹135 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+11.5-10.7+2.8—
EBITDA Growth—+25.5-6.2+7.9—
EBIT Growth—+34.2-7.8+5.2—
Net Income Growth—+184.3-3.3-12.2—
EPS Growth—+195.8-7.7-13.4—
Total Assets Growth—+2.3+4.8+11.9—
Total Equity Growth—+8.7+11.8+6.3—
Cash from Operations Growth—+1,330.0-93.7+48.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.